The collaboration will bring together ophthalmic image analysis from IDx and cognitive computing services from IBM. The two companies will help hospitals, health systems and integrated delivery networks provide value-based care to patients with eye conditions such as diabetic retinopathy and glaucoma.
The first phase of the agreement involves IBM Watson Health distributing IDx-DR, an automated solution that detects diabetic retinopathy. IDx-DR currently is available in 31 countries in Europe. IDx products have not been cleared by the U.S. Food and Drug Administration, but IBM Watson Health may expand its distribution to Australia, Canada and the United states upon regulatory approval.
More articles on health IT:
Health IT coalition questions ONC’s mission in letter to Price
Mount Sinai completes mHealth research project on asthma
4 questions with Lahey Health CIO David Reis
